Our Research
Pioneering next-generation therapies to combat aggressive, chemo-resistant cancers
Cancer remains one of the most challenging diseases to treat due to its ability to adapt, resist therapies, and spread throughout the body.
Effective treatments are urgently needed, especially for aggressive, chemo-resistant cancers. At Acomhal Research, we focus on connexin43 (Cx43) — a protein vital for cell-cell communication and often hijacked by cancer cells to support their growth and survival. Our approach utilizes a patented mimetic peptide of a specific sequence in the Cx43 carboxy-terminus tail, disrupting the protein interactions that cancer cells rely on to thrive. By breaking down these cellular connections, our new drug induces cancer cell death, providing a promising adjuvant therapy to combat even the most resilient forms of cancer.
A Different Approach to Cancer Treatment
Some cancers respond very well to chemotherapy, immunotherapy, radiation, surgical resection, and other interventions. At Acomhal Research, we study new ways to target and eliminate aggressive cancers that have historically resisted treatment and have a high rate of metastasis and recurrence.
How we aim to revolutionize cancer treatments and prevent tumor recurrence
Leveraging the scientific creativity and expertise of our team and partners, we are set to redefine the fight against cancer. Our is a dynamic blend of biotech entrepreneurs, distinguished scientific leaders, pharmaceutical experts, and clinicians. United by a shared mission, we are dedicated to advancing oncology science and transforming patient outcomes worldwide.
A Different Approach
Some cancers respond very well to chemotherapy, immunotherapy, radiation, surgical resection, and other interventions. At Acomhal Research, we study new ways to target and eliminate aggressive cancers that have historically resisted treatment and have a high rate of metastasis and recurrence.
How we aim to revolutionize cancer treatments and prevent tumor recurrence
Leveraging the scientific creativity and expertise of our team and partners, we are set to redefine the fight against cancer. Our is a dynamic blend of biotech entrepreneurs, distinguished scientific leaders, pharmaceutical experts, and clinicians. United by a shared mission, we are dedicated to advancing oncology science and transforming patient outcomes worldwide.
A Different Approach
Some cancers respond very well to chemotherapy, immunotherapy, radiation, surgical resection, and other interventions. At Acomhal Research, we study new ways to target and eliminate aggressive cancers that have historically resisted treatment and have a high rate of metastasis and recurrence.
